Based on the Novacyt stock forecast from 0 analysts, the average analyst target price for Novacyt is not available over the next 12 months. Novacyt’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Novacyt is Slightly Bullish , which is based on 5 positive signals and 3 negative signals. At the last closing, Novacyt’s stock price was GBX 61.00. Novacyt’s stock price has changed by +20.91% over the past week, +31.18% over the past month and +10.41% over the last year.
No recent analyst target price found for Novacyt
No recent average analyst rating found for Novacyt
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Prod...Read More
Frequently Asked Questions About Novacyt (NCYT:LSE) Stock
Stock Target Advisor's fundamental analysis for Novacyt's stock is Slightly Bullish .
Unfortunately we do not have enough data on NCYT:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on NCYT:LSE's stock to indicate what its average analyst target is.
NCYT:LSE stock's Price/Earning ratio is 1.29.
Our analysis grades NCYT:LSE stock's Price / Earning ratio at A+. This means that NCYT:LSE stock's Price/Earning ratio is above 0% of the stocks in the Medical Devices sector in the LSE exchange.
Based on this NCYT:LSE may be undervalued for its sector.
The last closing price of NCYT:LSE's stock was GBX 61.00.
The most recent market capitalization for NCYT:LSE is GBX 0.03B.
Unfortunately we do not have enough analyst data on NCYT:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Novacyt's stock.
As per our most recent records Novacyt has 120 Employees.
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NCYT:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
